Home / Pharmaceutical company intelligence
Mega Pharmaceuticals limited logo
Pharmaceutical company intelligence

Mega Pharmaceuticals limited

Public pharmaceutical manufacturer · Lahore · Pakistan

Lahore pharmaceutical manufacturer producing general and cephalosporin medicines and marketing a broad branded-generic portfolio.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date17 Aug 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Public pharmaceutical manufacturer
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
63%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000537 Mega Pharmaceuticals Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000537 128 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Exact site not yet sourced

No exact premises location is published without a defensible source.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx130public portfolio records represented
REG79unique registrations represented
IDX127indexed MedInfoBase presentations
SRC3additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR126current validated price records
G40generic molecules in indexed catalogue
DF4dosage-form groups
TA9therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage97%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage96%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMega Pharmaceuticals limitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mega-pharmaceuticals-limitedGenerated 23 Sep 2026Anti-infectives47 · 37%Cardiovascular24 · 19%CNS & mental health15 · 12%Respiratory & allergy12 · 9%Gastrointestinal & hepatology12 · 9%Pain & musculoskeletal9 · 7%Endocrine & metabolic6 · 5%Other therapeutic areas2 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMega Pharmaceuticals limitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mega-pharmaceuticals-limitedGenerated 23 Sep 2026127presentationsTablet82 · 65%Capsule27 · 21%Injection11 · 9%Suspension7 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMega Pharmaceuticals limitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mega-pharmaceuticals-limitedGenerated 23 Sep 2026117comparable productsBelow peer median47 · 40%Near peer median39 · 33%Above peer median31 · 26%Company median price position-1.5%Lowest-price equivalents12Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMega Pharmaceuticals limitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mega-pharmaceuticals-limitedGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,30 shared75% overlapMediate Pharmaceutical Pvt Ltd29 shared73% overlapZafa Pharmaceutical Laboratories (P…27 shared68% overlapNeutro Pharma (Pvt.) Ltd.,27 shared68% overlapBio-Labs(Pvt) Ltd26 shared65% overlapBarrett Hodgson Pakistan (Pvt.) Ltd26 shared65% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives47 products · 37%
Cardiovascular24 products · 19%
CNS & mental health15 products · 12%
Respiratory & allergy12 products · 9%
Gastrointestinal & hepatology12 products · 9%
Pain & musculoskeletal9 products · 7%
Endocrine & metabolic6 products · 5%
Vitamins, minerals & nutrition1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antipsychotics14 products · 11%
Third-generation cephalosporins12 products · 9%
Antihistamines12 products · 9%
Beta blockers11 products · 9%
Analgesics / NSAIDs9 products · 7%
Fluoroquinolone antibacterials9 products · 7%
Macrolide antibacterials7 products · 6%
First-generation cephalosporins6 products · 5%
Formulation footprint

Dosage forms

Tablet82 products
Capsule27 products
Injection11 products
Suspension7 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ATLAtenolol 6presentations 100 mg, 50 mg · Tablet #2 MegafastFexofenadine 6presentations 120 mg, 180 mg, 60 mg · Tablet #3 MegapolParacetamol 6presentations 500 mg · Tablet #4 MegazoleOmeprazole 6presentations 20 mg, 40 mg · Capsule #5 LeocinLevofloxacin 5presentations 250 mg, 500 mg, 750 mg · Tablet #6 MegadipAmlodipine 5presentations 10 mg, 5 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4740% of comparable products
Near market median39within ±5% of median
Above market median3126% of comparable products
Lowest-price equivalents12ties included
Company median price position -1.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Olanzar - F 25 mgOlanzapine · Capsule · 20's PKR 11.68/capsule-63.6% vs market median Megapol 500 mgParacetamol · Tablet · 10 x 10's PKR 1.75/tablet-51.9% vs market median Dawn 2 mgRisperidone · Tablet · 25 x 20's PKR 19.37/tablet-47.7% vs market median Olanzar - F 25 mgOlanzapine · Capsule · 20's PKR 19.54/capsule-39.1% vs market median Dawn 2 mgRisperidone · Tablet · 1 x 10's PKR 22.94/tablet-38.1% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 30shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 29shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 27shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 27shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 26shared generics Barrett Hodgson Pakistan (Pvt.) Ltd187 products · 63 generics 26shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers77Distinct registrations among indexed, published, presentation-validated products only
Verified price observations254
Products with a verified price127
Products with multiple price observations126
Source records with multiple versions127
Latest portfolio source check22 Sep 2026
Latest effective price date17 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

79 unique registration(s) · 127 indexed presentation(s) · 3 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
AgoutSource observed Allopurinol 300 mg Tablet 2x10's 057542Official source ↗ No indexed price — —
ATL Atenolol 50 mg Tablet 2x10's 037842 PKR 143.54 PKR 7.18/tablet Near median
ATL Atenolol 50 mg Tablet 1 x 20’s 037842 PKR 143.54 PKR 7.18/tablet Near median
ATL Atenolol 50 mg Tablet 25 x 20's 037842 PKR 3,030.77 PKR 6.06/tablet 16% below median
ATL Atenolol 100 mg Tablet 2x10's 037843 PKR 205.06 PKR 10.25/tablet Near median
ATL Atenolol 100 mg Tablet 25 x 10's 037843 PKR 2,164.95 PKR 8.66/tablet 17% below median
ATL Atenolol 100 mg Tablet 25 x 20's 037843 PKR 4,329.90 PKR 8.66/tablet 17% below median
Bisomeg Bisoprolol fumarate 2.5 mg Tablet 14's 110647 PKR 44.30 PKR 3.16/tablet 26% below median
Bisomeg Bisoprolol fumarate 5 mg Tablet 20's 110648 PKR 165.03 PKR 8.25/tablet 32% below median
Bisomeg Bisoprolol fumarate 10 mg Tablet 20's 110649 PKR 297.06 PKR 14.85/tablet 33% below median
Bravofen Ibuprofen 200 mg Tablet 10 x10’s 042880 PKR 249.58 PKR 2.50/tablet 10% above median
Bravofen Ibuprofen 200 mg Tablet 10 x 50's 042880 PKR 1,073.19 PKR 2.15/tablet 7% below median
Bravofen Ibuprofen 400 mg Tablet 25 x10’s 042881 PKR 913.13 PKR 3.65/tablet Near median
C-Span Cefixime 100 mg/5 mL Suspension 60 mL 032874 PKR 418.89 PKR 6.98/mL 33% below median
C-Span Cefixime 100 mg/5 mL Suspension 30 mL 032874 PKR 299.20 PKR 9.97/mL Near median
C-Span Cefixime 400 mg Capsule 1x5's 034336 PKR 563.10 PKR 112.62/capsule Near median
C-Span Cefixime 400 mg Capsule 10x5's 034336 PKR 5,964.14 PKR 119.28/capsule 6% above median
C-Span DS Cefixime 200 mg/5 mL Suspension 30 mL 068056 PKR 404.32 PKR 13.48/mL Near median
Cardiovastin Simvastatin 10 mg Tablet 1 x 20’s 032862 PKR 628.33 PKR 31.42/tablet 8% above median
Cardiovastin Simvastatin 10 mg Tablet 1 x 10's 032862 PKR 331.12 PKR 33.11/tablet 14% above median
Cardiovastin Simvastatin 20 mg Tablet 1 x 20’s 034335 PKR 947.48 PKR 47.37/tablet Near median
Cardiovastin Simvastatin 20 mg Tablet 1 x 10's 034335 PKR 498.67 PKR 49.87/tablet 9% above median
Celoxime Dry Powder Cefuroxime 750 mg Dry powder for injection Vial 047108 PKR 236.88 PKR 236.88/vial/unit 33% above median
CTZ Dry Powder Ceftriaxone 250 mg Dry powder for injection Vial 047102 PKR 201.46 PKR 201.46/vial/unit Near median
CTZ Dry Powder Ceftriaxone 500 mg Dry powder for injection Vial 047103 PKR 339.10 PKR 339.10/vial/unit Near median
CTZ Dry Powder Ceftriaxone 1 g Dry powder for injection Vial 047104 PKR 640.30 PKR 640.30/vial/unit Near median
Daisy Cetirizine 10 mg Tablet 25 x 20's 032865 PKR 4,319.44 PKR 8.64/tablet 8% above median
Daisy Cetirizine 10 mg Tablet 1 x 10's 032865 PKR 104.85 PKR 10.49/tablet 31% above median
Daisy Cetirizine 10 mg Tablet 1 x 20's 032865 PKR 176.37 PKR 8.82/tablet 10% above median
Daisy Cetirizine 10 mg Tablet 2 x 15's 032865 PKR 259.17 PKR 8.64/tablet 8% above median
Dawn Risperidone 2 mg Tablet 25 x 20's 037844 PKR 9,687.06 PKR 19.37/tablet 48% below median
Dawn Risperidone 2 mg Tablet 1 x 10's 037844 PKR 229.39 PKR 22.94/tablet 38% below median
Dawn Risperidone 4 mg Tablet 10's 111987 PKR 514.90 PKR 51.49/tablet 30% below median
Delexin Cephalexin 125 mg/5 mL Suspension 60 mL 048319 PKR 117.69 PKR 1.96/mL 6% above median
Delexin Cephalexin 250 mg/5 mL Suspension 60 mL 048320 PKR 203.46 PKR 3.39/mL 6% above median
Delexin Cephalexin 250 mg Capsule 12's 049078 PKR 203.46 PKR 16.96/capsule 11% above median
Delexin Cephalexin 500 mg Capsule 12's 049079 PKR 411.96 PKR 34.33/capsule 12% above median
Deprezac Fluoxetine 20 mg Capsule 10's 078946 PKR 129.66 PKR 12.97/capsule Near median
Ecogyl Metronidazole 400 mg Tablet 20's 080890 PKR 72.45 PKR 3.62/tablet 22% above median
Glide Gliclazide 80 mg Tablet 2 x 10's 032858 PKR 208.75 PKR 10.44/tablet 8% below median
Glimetica Glibenclamide + Metformin 250 mg + 1.25 mg Tablet 3x10's 057539 PKR 111.09 PKR 3.70/tablet No comparator
Glimetica Glibenclamide + Metformin 500 mg + 2.50 mg Tablet 2x10's 057540 PKR 137.63 PKR 6.88/tablet No comparator
Glucoban Glibenclamide 5 mg Tablet 6 x 10's 032859 PKR 172.21 PKR 2.87/tablet 20% above median
Glucoban Glibenclamide 5 mg Tablet 25 x 20’s 032859 PKR 1,150.02 PKR 2.30/tablet 18% below median
Glucoban Glibenclamide 5 mg Tablet 5 x 20’s 032859 PKR 239.58 PKR 2.40/tablet 14% below median
Leocin Levofloxacin 250 mg Tablet 10 x 10's 032888 PKR 3,303.22 PKR 33.03/tablet 32% below median
Leocin Levofloxacin 250 mg Tablet 1 x 10's 032888 PKR 359.05 PKR 35.91/tablet 26% below median
Leocin Levofloxacin 500 mg Tablet 5 x 10's 032889 PKR 2,652.95 PKR 53.06/tablet 33% below median
Leocin Levofloxacin 500 mg Tablet 1 x 10's 032889 PKR 558.52 PKR 55.85/tablet 29% below median
Leocin Levofloxacin 750 mg Tablet 10's 078940 PKR 997.35 PKR 99.74/tablet 7% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Mega Pharmaceuticals limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/mega-pharmaceuticals-limited/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.